The manufacturer recommends that patients using oral hormonal contraceptives switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after tirzepatide initiation and for 4 weeks after each dose escalation
More recently, their anti-inflammatory, cardioprotective, and neuroprotective properties have been explored in conditions such as cardiovascular disease (24), non-alcoholic fatty liver disease (25), osteoarthritis (26), rheumatoid arthritis (27), Alzheimers (28), and Parkinsons disease (29)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial
For patients with weight-management indications, monitoring for suicidality is recommended, as these medications carry warnings about suicidal thoughts and behaviors